The Clinical Cost of Delays in Switching Therapy by Sharon Walmsley

“…New guidelines suggest that the goal of therapy should be maximal virological suppression. This is best achieved by using combinations of agents to which the virus is most likely to have some susceptibility and, where possible, by using agents within a new therapeutic class. …”
Get full text

Treatment of Chronic Hepatitis C Infection among Current And Former Injection Drug Users within a Multidisciplinary Treatment Model at a Community Health Centre by Adam I Newman, Shelley Beckstead, David Beking, Susan Finch, Tina Knorr, Carol Lynch, Meredith MacKenzie, Daphne Mayer, Brenda Melles, Ron Shore

“…Of the 14 patients who initiated antiviral treatment in the study period, eight (57%) achieved sustained virological response. Regardless of virological outcome, patients who initiated treatment showed positive trends toward increased social and psychiatric stability, and decreases in high-risk behaviours. …”
Get full text

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

“…Sustained virologic response was achieved in 73 (80%) of patients available for analysis (n=91). …”
Get full text

Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients by Long-Shan Ji, Qiu-Tian Gao, Ruo-Wen Guo, Xin Zhang, Zhen-Hua Zhou, Zhuo Yu, Xiao-Jun Zhu, Ya-Ting Gao, Xue-Hua Sun, Yue-Qiu Gao, Man Li

“…To compare the clinical efficacy of the combination therapy with Bushen formula (BSF) plus entecavir (ETV) in naïve chronic hepatitis B (CHB) patients and that in CHB patients with partial virological response to ETV and explore the relevant immunoregulatory mechanism. …”
Get full text

Time to First-Line Antiretroviral Treatment Failure and Its Predictors among HIV-Positive Children in Shashemene Town Health Facilities, Oromia Region, Ethiopia, 2019 by Endale Zenebe, Assefa Washo, Abreham Addis Gesese

“…In resource-limited settings, treatment failure is often diagnosed based on the clinical or immunological criteria which occur way after the occurrence of virological failure. Previous limited studies have evaluated immunological and clinical failure without considering virological failure in Ethiopia. …”
Get full text

Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C by N. B. Kovaleva

“…At AVT, including Altevir® and ribavirin to CHC patients with 1b genotype of HCV and favorable prognosis of virologic response, 66% SVR rate can be achieved.…”
Get full text

Hyperferritinemia at the patient with chronic hepatitis C by Ye. N. German, A. O. Buyeverov, M. V. Mayevskaya, Ch. S. Pavlov, V. T. Ivashkin, A. A. Levina

“…After cessation of the treatment course clinical and laboratory abnormalities reduced. Sustained virologic response was ascertained.…”
Get full text

Viral Response to Specifically Targeted Antiviral Therapy for Hepatitis C and the Implications for Treatment Success by Curtis L Cooper

“…Collectively, specifically targeted antiviral therapy for HCV (STAT-C) molecules achieve rapid viral suppression and very high rapid virological response rates, and improve sustained virological response rates. …”
Get full text

STORAGE OF PIGLET KIDNEYS AT SUBNORMAL TEMPERATURES FOR PRIMARY TRYPSINIZED CELL MONOLAYER PREPARATION by B. L. Manin, N. V. Koropova, V. A. Starikov, I. V. Vologina

“…Optimization of the technology for preparation of the primary cells suitable for virological studies requires long-term storage of internal organs and tissues. …”
Get full text

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study by Hernando Knobel, Esperanza Cañas-Ruano, Ana Guelar, Pablo Knobel, Judit Villar-García, Alicia González-Mena, Ceclia Canepa, Itziar Arrieta-Aldea, Augustin Marcos, Agustí Abalat-Torrres, Roberto Güerri-Fernández

“…The primary objective was to evaluate treatment discontinuation rates; safety and virologic outcomes were also evaluated. Results 690 PLWH were included, 358 in the D/L and 332 in the B/F/T, and a median follow-up of 728 and 1013 days, respectively. …”
Get full text

48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse by Wen-xiong Xu, Qian Zhang, Xiang Zhu, Chao-shuang Lin, You-ming Chen, Hong Deng, Yong-yu Mei, Zhi-xin Zhao, Dong-ying Xie, Zhi-liang Gao, Chan Xie, Liang Peng

“…Age, HBsAg level, and origin HBeAg status can be predictive factors for virologic relapse. The study was submitted to ClinicalTrials.gov Protocol Registration and Results System with the assigned NCT ID NCT02883647.…”
Get full text

Perceived neighborhood disorder and achieving HIV viral suppression among adults living with HIV: A cross-sectional study. by Linda Jepkoech Kimaru, ChengCheng Hu, Sudha Nagalingam, Priscilla Magrath, Elizabeth Connick, Kacey Ernst, John Ehiri

“…This study aims to assess the relationship between perceived neighborhood disorder and achieving virologic suppression among people living with HIV. …”
Get full text

Optimizing Hepatitis C Therapy in HIV/hepatitis C Virus (HCV) Coinfected Patients: Analysis of HCV Viral Kinetics on Treatment by Paul Damien James, David KH Wong

“…INTRODUCTION: Hepatitis C virus (HCV) infection is potentially curable, but the sustained virological response (SVR) has been shown to be lower in patients coinfected HIV. …”
Get full text

Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C by Louis WC Liu, George Tomlinson, Tony Mazzulli, Alison Murray, Jenny Heathcote

“…Furthermore, less than 50% of patients overall have a sustained virological response (SVR).…”
Get full text

SARS-CoV-2: Molecular Structure, Pathogenesis, Potential Therapeutic Targets, and Immune Response of the Infected Subject by R. Wumba, M. Mandina, Y. Nlandu, J. R. Makulo, A. Tshimpi, P. Mbala, A. Mbangama, P. Kabututu, J. M. Kayembe

“…Through a documentary review of literature, the authors describe virological and molecular aspects of SARS-CoV-2, the intimate mechanisms of cell infection, and potential therapeutic targets. …”
Get full text

Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis by Yaqin Chen, Gang Wu, Hongmin Zhang, Hua Xu, Hong Li, Ling Chen, Yixuan Yang, Peng Hu, Dazhi Zhang, Hong Ren, Huaidong Hu

“…The treatment group was found to have higher virological response (VR) rates than controls at 12, 24, 48, and 72 weeks. …”
Get full text

Influenza Surveillance in an Urban Area by W Paul Glezen

“…In Houston the yearly influenza epidemics have been defined virologically by community surveillance obtained by testing specimens submitted from patients with acute respiratory illnesses seen by sentinel physicians. …”
Get full text

HIV RNA Suppression and Immune Restoration: Can We Do Better? by Marilia Rita Pinzone, Michelino Di Rosa, Bruno Cacopardo, Giuseppe Nunnari

“…HAART has significantly changed the natural history of HIV infection: patients receiving antiretrovirals are usually able to control viremia, even though not all virological responders adequately recover their CD4+ count. …”
Get full text

Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin by Morris Sherman, Lawrence Cohen, Mary Anne Cooper, Magdy Elkashab, Victor Feinman, David Fletcher, Nigel Girgrah, Jenny Heathcote, Mark Levstik, William B McNaull, David Wong, Florence Wong, Colina Yim

“…Today, combination antiviral therapy with pegylated interferon-alpha and ribavirin (RBV) allows many patients infected with hepatitis C virus (HCV) to achieve a sustained virological response, which is equivalent to cure. Data also support the clinical benefit of combination antiviral therapy in patients coinfected with HCV and HIV, and in patients who have received a liver transplant.…”
Get full text

Efficacy and safety of 3D-therapy at HCV-related subcompensated liver cirrhosis (genotype 1b) by P. O. Bogomolov, M. V. Matsiyevich, A. O. Buyeverov, V. D. Beznosenko, Ye. V. Fedosova, M. Yu. Petrachenkova, S. V. Koblov, K. Yu. Kokina, O. S. Kuzmina, N. V. Voronkova

“…The causes of inefficacy of previous modes of combined antiviral therapy (CAT) included absence of virologic response in 43.9% of the cases, recurrence of HCV replication - in 30.3%, virological breakthrough - in 16.7%, development of serious adverse effects - in 9.1%. …”
Get full text